McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Kevin Noonan is quoted in a January 9, 2017 online edition of Gizmodo.com in an article entitled, “Why the Patent Battle Over CRISPR Matters (and Why It Doesn’t).” By the time a panel of judges at the U.S. Patent and Trademark Office gets around to deciding who owns the biggest biotechnology innovation of the century, CRISPR-Cas9 may have already lost its heavyweight title as the most precise tool for genetic engineering. View the article